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Determination of myocardial and serum digoxin 
concentrations in children by specific and 
nonspecific assay methods 
After obtaining samples at open heart surgery, serum and right atrial digoxin concentrations 
were measured in 25 children by a nonspecific, direct radioimmunoassay method (NS) and 
by a specific method in which digoxin was separated from its metabolites by HPLC before 
radioimmunoassay was applied to the digoxin fraction (S). Digoxin was detectable by S assay 
(sensitivity 0.1 nglg) in 16 heart specimens and 22 serum samples. The mean and range of the 
SINS ratio was 0.74 (0.23 to 2.63) for serum and 0.81 (0.068 to 1.38) /or atrial tissue. By NS 
assay the mean and range of the atrial /serum ratio was 78.1 (2.4 to 340, n = 21) and by S 
assay the corresponding values were 100 (10.7 to 318, n = 15). A multiple linear regression 
indicated that 72.5% of the variance of the heart digoxin concentrations measured by S assay 
were accounted for by the variables height, body weight, daily digoxin dose before operation, 
plasma digoxin concentration by S assay, and BUN. 
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The therapeutic activity of digoxin has been 
related, at least in part, to the concentration of 
the drug in myocardium, which, in turn, should 
be related to the serum leve1.22 Although the 
earliest studies4,10,11,20 in which myocardial di- 
goxin concentrations were measured involved 
the administration of 3H-digoxin to the patients 
and were nonsteady-state studies, all subse- 
quent studies8,9,18,19,22,23,26,32 have been steady- 
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state studies and have involved the use of radio- 
immunoassay (RIA) to measure digoxin con- 
centrations in both heart tissue and serum or 
plasma. With the use of these techniques, di- 
goxin concentrations have been shown to differ 
among various sites within the human heart,3.9'23 
but not during cardiopulmonary bypass.4,20,26 
Myocardial digoxin/plasma or serum digoxin 
mean ratios appear to be considerably higher in 
infants (51 yr of age) than in adults, but only 
two studies appear to have been carried out in 
children (excluding infants). The study of Her- 
nandez et al.2° was a nonsteady-state study and 
involved digitalization of nine children with 
3H-digoxin just 2 days before open heart sur- 
gery. The study of Krasula et al.26 in 42 chil- 
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dren involved 18 children who had been receiv- 
ing maintenance digoxin for a month or longer 
and the authors reported a mean right atrial 
appendage (RAA) digoxin concentration of 62 
ng/gm and a mean serum digoxin concentration 
of 1.2 ng/ml in the latter. However, they re- 
ported no individual patient data. 
One of the authors35 of the present report has 
shown that the digoxin metabolites digoxi- 
genin-mono-digitoxoside, digoxigenin-bis-digi- 
toxoside , and digoxigenin cross react exten- 
sively in RIA. Kramer et al.25 showed that dihy- 
drodigoxin also cross reacts. Recently digoxin 
has been separated from its metabolites by HPLC 
in small enough samples to make the technique 
applicable to the therapeutic situation. If the di- 
goxin fraction at the end of the HPLC column is 
collected, and by either applying the RIA or 
measuring radioactivity when radiolabeled di- 
goxin was used, specific assay methods for di- 
goxin have been made available.13'28-31 Also, a 
more complicated assay, involving different 
methods and the use of radiolabeled digoxin, 
has been described." 
With presently available assay methods, stud- 
ies have been carried out to determine to what 
degree digoxin concentrations measured by the 
specific (S) and the conventional nonspecific 
(NS) RIA differ. Gibson and Ne1son1647 re- 
ported that plasma digoxin concentrations mea- 
sured by specific HPLC assay and direct 125I-RIA 
are essentially identical when glomerular fil- 
tration rate is 40 ml/ min or more; in contrast 
the ratio of SINS values was 0.83 ± 0.12 
(mean SD) in renal failure patients. Wagner 
et al.37 reported no significant differences be- 
tween results with a specific assay3° and the 
3H-digoxin RIA" with groups of 17 randomly 
selected plasma samples and 34 randomly se- 
lected urine samples from a study in normal 
adult male subjects. Loo et al." reported a 
mean ratio of SINS digoxin in serum of 
0.84 ± 0.12 in 14 digitalized patients of un- 
known renal status. Gault et al." reported con- 
siderably larger percentages of a single dose of 
3H-digoxin excreted in the urine in 5 days as 
unchanged digoxin and metabolites in six pa- 
tients with normal renal function compared with 
six patients with minimal renal function. 
Our purposes were to measure myocardial 
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and serum digoxin concentrations in children, 
on whom available information is minimal, and 
to compare results of the nonspecific direct RIA 
with results obtained with a new specific HPLC- 
RIA method. 
Methods 
The study population consisted of 25 children 
from 9 mo to 18 yr old who were undergoing 
intracardiac repair of various congenital heart 
defects. Each child had been taking digoxin 
over a long term (21 mo) for up to 24 hr before 
open heart surgery. A 5- to 10-ml blood sample 
was obtained during operation before car- 
diopulmonary bypass; part of the blood was 
used for serum creatinine determination and the 
remainder was converted to serum and quick- 
frozen for digoxin assays at a later date. A heart 
tissue sample from the right atrial appendage, 
routinely removed for cannulation and dis- 
carded, was obtained just before the institution 
of cardiopulmonary bypass. Fat tissue was 
removed; the tissue was then frozen and stored 
at 20°. 
The frozen tissue samples were thawed at one 
time and their wet weights measured (range 40 
to 250 mg); the samples were then lyophilized 
in 15-ml screw-top test tubes. The lyophilized 
cake was finely ground with a glass rod and any 
dried tissue remaining on the rod was washed 
into the bottom of the tube with a small volume 
of methylene chloride. Internal standard solu- 
tion (100 ill of a 20 1)4 solution of ethoxzola- 
mide in water) was added along with 4 ml of 
methylene chloride. The tubes were capped, 
vigorously shaken for 10 min, gently cen- 
trifuged, then the methylene chloride extract 
was transferred to a clean test tube. The extrac- 
tion procedure was repeated three times to give 
a final methylene chloride extract volume of 
about 12 ml. This extract was divided into two 
portions and each was evaporated to dryness to 
provide dry residues for the S and NS assays. 
For the S assay the residue was reconstituted in 
150 Al of methanol and 3 Al of a 2-mg/m1 solu- 
tion of nalorphine was added as a marker. This 
marker was chosen since the end of its peak, 
measured in the UV (254 nm), coincided with 
the beginning of elution of the digoxin fraction. 
Of this mixture 100 Al was injected onto the 
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HPLC column. Standard curves were prepared 
by spiking lyophilized dog heart samples (250 
mg wet weight) with digoxin over a range of 4 to 
200 ng/gm wet tissue and processing as de- 
scribed above. Digoxin concentrations in the 
human RAA samples were calculated with refer- 
ence to these standard curves and the concentra- 
tions are expressed as nanograms of digoxin per 
gram wet atrium. It is feasible that by the use of 
methylene chloride to extract digoxin from 
heart tissue one or more metabolites of digoxin 
were excluded from the organic extract and left 
in the aqueous phase, thus making the NS heart 
assay inherently more specific than the NS se- 
rum assay, in which extraction was not involved. 
For the specific assay of serum 1 ml of 
serum, 100 pi of a 20 pg/m1 solution of ethox- 
zolamide as internal standard, 50 Al of 1.5M 
HO, and 12 ml of methylene chloride were 
placed in a 15-ml test tube with a Teflon-lined 
screw cap in place. The tube was shaken for 10 
min then centrifuged for 5 min at 2500 rpm. 
The supernatant aqueous layer was discarded 
and the organic layer was transferred to a 10-ml 
test tube; the extract was then evaporated to 
dryness with a stream of nitrogen. Just before 
chromatography the dried residue was reconsti- 
tuted in 150 ,u1 of methanol and 3 pl of a 
2-mg/m1 solution of nalorphine was added as 
marker. Of this, 100 pi was injected onto the 
HPLC column. 
The S assay for both serum and atrial tis- 
sue was an adaptation of the method of Morais 
et al.36 in which a different internal standard, 
marker, and chromatography method were used. 
The chromatography system consisted of an 
LDC minipump (Milton Roy), a C-18 p.- 
Bondapak column (Waters Associates), and a 
model HM Holochrome variable-wavelength de- 
tector (Gilson Medical Electronics). Samples 
were loaded onto the column with a Rheodyne 
7010 loop injector (Rheodyne Ltd.). The eluting 
solvent was 30% acetonitrile, 70% 0.025M 
KH2PO4, buffered to pH 6.9 with IN KOH. The 
flow rate was 3 ml min-1. The detector wave- 
length was 254 nm at 0.02 AUFS. The eluent 
fraction between the end of the nalorphine peak 
and the beginning of the ethoxzolamide peak was 
collected and this fraction had been shown to be 
the one containing the digoxin. The fraction col- 
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lected was evaporated to dryness at 370 under a 
stream of air. To the residue from the latter 
(obtained from either plasma or heart tissue) was 
added 1 ml of digoxin-free plasma and the RIA 
as described by Wagner et al .36 was carried out. 
The NS assay for plasma was carried out with 
1 ml of the patient plasma rather than the 
digoxin-free plasma and residue as described 
above. The NS assay for the RAA samples was 
carried out by adding 1 ml of digoxin-free 
plasma to the residue from the methylene chlo- 
ride extract above. In both cases the RIA as de- 
scribed by Wagner et al.36 was then carried out. 
Statistics. The correlation coefficient (r) and 
standard deviation of scatter about regression 
value (s) were calculated with equations 1 and 2 
as follows: 
i>)2 
r = V 1 
(Y Y)2 
(1) 
s = (2) 
N 
where Y is the observed value of the dependent 
variable, i> is the estimated value of the depen- 
dent variable, Y is the average value of the de- 
pendent variable, N is the number of data 
points, and P is the number of parameters es- 
timated. 
Results 
Table I lists demographic data along with 
serum and RAA digoxin concentrations mea- 
sured by NS and S assay methods. Digoxin was 
detectable in 22 of 25 RAA samples by NS 
assay, but only in 16 of 25 by S assay. Digoxin 
was detectable in 24 out of 25 serum samples by 
NS assay, but in only 22 out of 25 by S assay 
(with a sensitivity limit of 0.1 ng/ml). Averages 
and ranges were: serum digoxin by NS assay, 
0.809 (0.062 to 1.89) ng/ml; serum digoxin by 
S assay, 0.520 (<0.1 to 1.26) ng/ml; RAA di- 
goxin by NS assay, 48.1 (1.2 to 178) ng/gm 
wet; RAA digoxin by S assay, 48.7 (2.6 to 159) 
ng/gm wet; RAA/serum ratio, 78.1 (2.4 to 340) 
by NS assay and 84.7 (omitting patient N. R.) 
(10.7 to 190) by S assay; S/NS ratio, 0.74 (0.23 
to 2.63) for serum and 0.81 (0.062 to 1.38) 
for RAA. 
Various correlations were examined in which 
RAA digoxin concentrations by S assay were 
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Table I. Demographic data and digoxin concentrations in serum and RAA tissue 
by S and NS assay 
ND = not detectable. 
*These 15 patients were grouped together for the correlations described in Results, as were the remaining 14 patients. 
correlated with either individual variables, in- 
cluding age, height, body weight, lean body 
mass, dose of digoxin, BUN, serum creatinine 
concentration, body surface area, and serum di- 
goxin, or with various combinations of multiple 
variables. For these correlations n = 15 (indi- 
cated in Table I) or n = 14 (omitting patient 
N. R.). Most single independent variable corre- 
lations gave correlation coefficients in the range 
0.2 to 0.4. The exception was when Y RAA 
digoxin and X = plasma digoxin, both by S 
assay, and n = 14, which gave: 
= 18 + 40X (r = 0.697; (3) 
0.001 > P > 0.01; s = 16.1 ng/gm) 
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For the same 14 patients the NS assay results 
gave the nonsignificant r value of 0.526 with an 
intercept of 34 and a slope of 24. 
The best multiple correlation found with the 
S assay results was as follows: 
= 183 + 0.552 XI - 3.42 X2 + (4) 
7.54 X3 ± 0.322 X4 + 36.8 X5 
(n = 14;r = 0.852; 0.02> P > 0.01; s = 14.4 ng/gm) 
where Y is the estimated RAA digoxin concen- 
tration (ng/gm wet), X, is BUN (mg/di), X2 is 
height (cm), X, is body weight (kg), X4 is di- 
goxin dose (i..ts/day), and X, is plasma digoxin 
concentration by S assay (ng/ml). Use of lean 
Patient Sex 
Age 
(yr) 
Body 
weight 
(kg) 
Height 
(or) 
Surface 
area 00 
Serum 
creat. 
(mg IN) 
ilmv 
(mgh10 
Dig. 
dose 
(jig b.i.d.) 
A. B.* 3.5 11.2 76 0.46 0.3 16 30 
J. C.* 2.5 5.7 65.5 0.3 0.5 11 28 
C. F.* 2. 5.5 67 0.3 0.4 11 25 
D. G.* 3 7.42 76 0.39 0.3 11 45 
E. H.* 2 4.40 64 0.27 0.3 8 20 
C. H.* 3 6.64 68 0.34 0.3 14 35 
D. H.* 2 7.1 70 0.36 0.2 9 30 
J. S.* 3.5 8.26 81 0.22 0.5 20 25 
C. T.* 2 4.0 57 0.24 0.3 7 18 
R. H. 5 12.8 93 0.57 0.4 15 45 
A. B. 4 13.1 96 0.59 0.4 13 50 
N. B. 3 7.56 71.5 0.37 0.4 10 30 
W. C. 5.5 8.22 77 0.4 0.4 21 35 
F. F.* 3 9.5 82 0.45 0.3 15 50 
T. K.* 2.5 7.38 73 0.38 0.5 18 35 
B. L. 18 88.0 173 2.02 1.0 12 125 
B. R. 2 7.6 73 0.38 0.2 10 30 
K. R.* 1 7.4 71.5 0.37 0.5 33 25 
T. C. 4 9.8 91 0.50 0.5 14 50 
A. W.* 13 31.0 140 1.11 0.8 17 100 
D. A. 1 4.26 57 0.18 0.4 14 22.5 
A. S. 15 96.0 165 2.02 1.1 18 250 
S. J. 1.5 5.7 68 0.32 0.4 10 25 
N. R.* 0.75 3.7 55 0.23 0.4 8 17 
A. H. 10 18.1 108 0.73 0.8 5 70 
Average 
Average w/o N.R. 
CV (%) 
Volume 33 
Number 5 
body mass2i instead of total body weight de- 
creased the correlation coefficient slightly to 
0.834, although previous data1'14'21 had sug- 
gested that lean body mass was preferable to 
total body weight in estimating dose of digoxin. 
NS results for the same 14 patients and vari- 
ables gave r = 0.810, but when all 21 available 
data sets were used the r value dropped to 
0.587. Use of body weight and height as vari- 
ables gave higher correlation coefficients than 
when body surface area, which was estimated 
by nomograph from weight and height, was 
used. The ratio of SINS for RAA (Y) correlated 
with BUN (X) as follows: 
= 1.185 - 0.0296X (n = 16; (5) 
r = 0.608; 0.02 > P > 0.01) 
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but not with serum creatinine concentration. The 
same ratio for serum, however, correlated poorly 
with BUN (n = 22; r = 0.104; P> 0.10). 
Correlation of NS assay results (Y) with S 
results (X) gave: 
It should be noted that the means of 48.1 and 
48.7 ng/gm for NS and S assays of RAA tissue 
(Table I) are somewhat misleading since the NS 
mean is based on 22 patients while the S mean 
is based on only 16 patients. For the 16 patients 
in whom NS and S tissue values were available, 
for each patient the mean ratio of SINS is 0.81 
and for 12 out of the 16 the ratio is less than 
unity. For the same 21 patients in whom both 
NS and S values are available for serum (but 
excluding patient B. L. because of spuriously 
low NS digoxin concentration) the mean SINS 
ratio is 0.651 and for 19 out of 21 the ratio is 
less than unity. These results, together with the 
two correlations shown as equations 6 and 7 
above, imply that appreciable amounts of me- 
tabolites were measured by NS assay, and that 
the proportion of metabolites measured in heart 
tissue by NS assay was less than that measured 
in plasma. 
Discussion 
Two important observations emerged from 
this study. First, the mean RAA/serum digoxin 
ratio of 78 observed among our children fell in 
the intermediate zone between the mean ratio 
(23.9's to 2832) reported for adults on the one 
hand and that reported for infants (14932) on the 
other. Among our 25 children, three (K. R., 
D. A., N. R.) were infants yr old). The 
youngest of these (N. R., 0.75 yr) exhibited the 
highest RAA digoxin concentration and the 
highest RAA/serum ratio by both NS and S 
assays. 
Although the absolute amount of digoxin 
may differ, as noted3'3'23 among different sites 
within the heart in man, but perhaps not in other 
species,' the ratio between tissue and serum 
Serum 
digoxin 
(ng 1ml) 
RAA 
digoxin 
(nglg) 
Rat io: 
RAA I erum 
NS NS NS 
0.530 0.297 83.4 56.5 157.0 190.0 
0.960 0.716 51.9 56.7 53.8 79.2 
1.14 1.14 61.0 73.0 53.5 64.0 
0.604 0.454 44.7 42.1 74.0 92.7 
1.13 0.738 44.8 43.5 39.6 58.9 
0.975 0.848 74.8 59.0 76.7 69.6 
0.90 1.05 40.3 28.4 44.8 27.0 
0.644 0.242 38.3 2.6 59.5 10.7 
0.424 0.269 40.6 40.9 95.8 152.0 
0.365 <0.1 5.5 ND 15.1 
0.580 0.412 45.9 ND 79.1 
0.493 0.484 1.18 ND 2.4 
1.89 5.7 ND 3.0 
0.371 0.320 39.6 17.5 107.0 54.7 
1.62 1.26 81.7 77.0 50.4 61.1 
0.062 0.163 21.1 ND 340.0 
0.482 0.176 13.5 ND 28.0 
0.943 0.213 63.9 30.7 67.8 144.0 
0.300 0.16 ND ND 
0.429 0.242 36.9 20.7 86.0 85.5 
1.45 1.04 ND ND 
0.935 0.434 ND ND 
1.03 0.288 55.3 27.7 53.7 96.2 
1.17 0.501 177.6 159.1 152.0 318.0 
ND <0.1 31.6 43.5 
0.809 0.520 48.1 48.7 78.1 100.0 
74.4 84.7 
55.4 66.8 77.0 73.2 92.8 76.5 
For RAA: )^( = 16.7 + 0.898X (6) 
(n = 16; r = 0.904; P < 0.001) 
For serum: i'L7 = 0.32 + 0.885X (7) 
(n = 22; r = 0.782; P < 0.001) 
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digoxin appears to be reasonably constant. Goro- 
discher et al.'8 reported a mean left ventricu- 
lar/serum digoxin ratio of 146 among eight in- 
fants, of the order of the ratio found by Park 
who used the right atrial appendage.32 Other 
investigators have shown a left ventricular/se- 
rum digoxin ratio of 3522 to 57" and 22 to 7738 
in adults, also of the order of Park's adult data. 
In contrast to the above experience demonstrat- 
ing age-related but not anatomic site differences 
in serum/tissue digoxin ratios, Lang et al." and 
Kim et al 24 did not find age-related differences 
in ventricular myocardial/plasma concentration 
ratios measured in postmortem human material 
(an observation that was supported experimen- 
tally in fetal lambs and ewes by Berman et al.5). 
Reasons for this discrepancy within the studies 
involving human subjects are not clear, but are 
probably do to the different myocardial sites, 
the use of postmortem material, and the differ- 
ences in dose per kilogram body weight. 
To examine factors that might predict the 
RAA concentration in our subjects, several 
multiple regression analyses were performed. It 
was found that 72.5% of the variance of the 
RAA digoxin concentration by specific assay 
could be accounted for by BUN concentration, 
height, body weight, digoxin dose, and digoxin 
serum concentration (equation 4). Similar corre- 
lations derived from data from the literature are 
not feasible since almost no authors report the 
individual patient values of such variables. An 
exception was the data of Jusko and Wein- 
traub,' who reported similar variables except 
for absence of the individual patient doses of 
digoxin. A multiple correlation with their data 
on 15 adults gave the equation: 
= 1.93 0.269X1 + 0.747X2 + 26.9X3 (8) 
(n 15; r 0.815; P < 0.001; s = 39.9 ng/gm) 
where Y.' is the estimated left ventricular digoxin 
concentration by NS assay, X, is the body 
weight (kg), X2 is serum creatinine concentra- 
tion (ml/min/1.73 m2), and X3 is the serum di- 
goxin concentration by NS assay (ng/ml). 
Thus, because age per se as a continuous inde- 
pendent variable is not a good predictor of RAA 
concentration, whereas other factors such as 
weight, height, and renal function along with 
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dose schedules are important determinants of 
the myocardial concentration in both children 
(equation 4) and adults (equation 8), our analy- 
sis, as well as recent experimental work in 
sheep,' does not support the widespread view 
that young myocardium cumulates (binds) 
digoxin more avidly than does adult myocar- 
dium at the same serum concentration 32 
The second important observation emerging 
from our study was the S/NS digoxin RAA ratio 
of 0.81. This ratio indirectly expresses the rela- 
tionship between digoxin and its metabolites. A 
direct relationship between this ratio and age 
would suggest increased metabolic turnover of 
digoxin in the young and help explain the need 
and use for larger doses in infants and children. 
Analysis of our data yielded no such relation- 
ship. This finding, coupled to the observation7 
of a similar ratio in both lambs (0.8) and ewes 
(0.77) given digoxin supports the view that 
age-related differences in the effects (and uses) 
of digoxin are not due to variation in drug me- 
tabolism. 
In summary, our data suggest that variation 
in RAA digoxin concentrations and digoxin 
serum/tissue ratios in children result, in large 
part, from variation in patient size and the di- 
goxin dose used, and not from age-related dif- 
ferences in myocardial digoxin binding or me- 
tabolism. These observations support the rec- 
ommendations33'34 regarding reduction in the 
amount of digoxin used in pediatric patients, 
particularly in small infants. 
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